BIOSETTIA, INC.

Biotech · Private

Deep sequencing-based biomarker assay measuring ERV Gag gene variants to detect autoimmune activation and predict type 1 diabetes progression

Grants
$292K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Targeting endogenous retrovirus Gag genes for biomarker development in type 1 diabetes$291,949
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3051Alentis Therapeutics——
3052OLFA THERA, INC.——
3053Pharmareview Corporation——
3054BIOSETTIA, INC.——
3055VEANA THERAPEUTICS LLC——
3056NANONEWRON LLC——
3057CatalYm——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.